Market Cap 1.75B
Revenue (ttm) 123.67M
Net Income (ttm) -38.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.24%
Debt to Equity Ratio 0.00
Volume 2,293,200
Avg Vol 942,600
Day's Range N/A - N/A
Shares Out 84.48M
Stochastic %K 94%
Beta 1.60
Analysts Strong Sell
Price Target $32.33

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2643
Address:
321 Harrison Avenue, Suite 900, Boston, United States
LabPsycho
LabPsycho Jun. 24 at 4:56 PM
$GLUE If Roche was willing to cough up an astonishing $700 million UPFRONT to NRIX protein degrader for codevelopment their leukemia drug, what might any of the many programs GLUE has in even bigger markets than CLL be worth?
1 · Reply
LabPsycho
LabPsycho Jun. 24 at 4:35 PM
$GLUE @cheruskian I am wondering how many if any besides me, have combed over GLUE ~ 100 PAGE!! May 2026 Corporate Presentation. So many projects, R&D and collaborations with several moving in to Phase 2 with big Pharma - GLUE itself is looking like a fledgling big pharma. Recent quarterly update in this link touches on some of their projects, progress and expected milestones. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-first-quarter-2026-financial
1 · Reply
ap20
ap20 Jun. 24 at 3:16 PM
$GLUE Nice run continues. ‘Need to snag a few more.. Stick with GLUE.
0 · Reply
oceanbleu
oceanbleu Jun. 24 at 1:58 PM
$GLUE needs to get through the 21.7 pivot associated with the 20.8-21 resistance zone and the odds will be good for progression to 24$.
0 · Reply
Firatyas
Firatyas Jun. 23 at 5:25 PM
0 · Reply
BuckeyeInvestor
BuckeyeInvestor Jun. 23 at 5:22 PM
$GLUE nice move!
0 · Reply
MuchMillions
MuchMillions Jun. 23 at 5:02 PM
$GLUE news dropping soon?
1 · Reply
oceanbleu
oceanbleu Jun. 17 at 3:43 PM
$GLUE I posted this daily chart last week with recommendation to buy at 16-16.3 area with a stop either at 11.5 or 13.6. I added to my original 16.3 position at retest and will trim this new position at 19.5 to give some cushion to my initialk position.
1 · Reply
ap20
ap20 Jun. 17 at 2:38 PM
$GLUE Stick with GLUE.
0 · Reply
wRsYUeX
wRsYUeX Jun. 11 at 1:35 AM
0 · Reply
Latest News on GLUE
Monte Rosa Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Monte Rosa Therapeutics Earnings release: Q1 2026


Monte Rosa Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Monte Rosa Therapeutics Quarterly report: Q1 2026


Monte Rosa Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 7 weeks ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M

2026-03-17T15:05:52.000Z - 3 months ago

Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M


Monte Rosa Therapeutics Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Annual report: Q4 2025


Monte Rosa Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Earnings release: Q4 2025


Monte Rosa Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics files automatic mixed securities shelf

2026-02-11T21:40:21.000Z - 4 months ago

Monte Rosa Therapeutics files automatic mixed securities shelf


Monte Rosa Therapeutics announces $200M common stock offering

2026-01-07T21:05:48.000Z - 6 months ago

Monte Rosa Therapeutics announces $200M common stock offering


Monte Rosa Therapeutics Transcript: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics announces Phase 1 data of MRT-8102

2026-01-07T12:10:51.000Z - 6 months ago

Monte Rosa Therapeutics announces Phase 1 data of MRT-8102


Monte Rosa Therapeutics Transcript: Study Result

Dec 16, 2025, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Dec 16, 2025, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Dec 16, 2025, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Earnings release: Q3 2025


Monte Rosa Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Quarterly report: Q3 2025


Monte Rosa Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Monte Rosa Therapeutics Earnings release: Q2 2025


Monte Rosa Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Monte Rosa Therapeutics Quarterly report: Q2 2025


Monte Rosa Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q1 2025


Monte Rosa Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q1 2025


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024


Monte Rosa Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Annual report: Q4 2024


Monte Rosa Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q4 2024


Monte Rosa Therapeutics Slides: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Slides: Q4 2024


Monte Rosa Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q3 2024


Monte Rosa Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Earnings release: Q3 2024


This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 3:06 PM EDT - 1 year ago

This Biotech Stock Has Doubled Its Value Today—Here's Why


Monte Rosa Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q2 2024


Monte Rosa Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q2 2024


Monte Rosa Therapeutics Announces Leadership Team Promotions

May 30, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Leadership Team Promotions


Monte Rosa Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q1 2024


Monte Rosa Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q1 2024


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q4 2023


Monte Rosa Therapeutics Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Annual report: Q4 2023


LabPsycho
LabPsycho Jun. 24 at 4:56 PM
$GLUE If Roche was willing to cough up an astonishing $700 million UPFRONT to NRIX protein degrader for codevelopment their leukemia drug, what might any of the many programs GLUE has in even bigger markets than CLL be worth?
1 · Reply
LabPsycho
LabPsycho Jun. 24 at 4:35 PM
$GLUE @cheruskian I am wondering how many if any besides me, have combed over GLUE ~ 100 PAGE!! May 2026 Corporate Presentation. So many projects, R&D and collaborations with several moving in to Phase 2 with big Pharma - GLUE itself is looking like a fledgling big pharma. Recent quarterly update in this link touches on some of their projects, progress and expected milestones. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-first-quarter-2026-financial
1 · Reply
ap20
ap20 Jun. 24 at 3:16 PM
$GLUE Nice run continues. ‘Need to snag a few more.. Stick with GLUE.
0 · Reply
oceanbleu
oceanbleu Jun. 24 at 1:58 PM
$GLUE needs to get through the 21.7 pivot associated with the 20.8-21 resistance zone and the odds will be good for progression to 24$.
0 · Reply
Firatyas
Firatyas Jun. 23 at 5:25 PM
0 · Reply
BuckeyeInvestor
BuckeyeInvestor Jun. 23 at 5:22 PM
$GLUE nice move!
0 · Reply
MuchMillions
MuchMillions Jun. 23 at 5:02 PM
$GLUE news dropping soon?
1 · Reply
oceanbleu
oceanbleu Jun. 17 at 3:43 PM
$GLUE I posted this daily chart last week with recommendation to buy at 16-16.3 area with a stop either at 11.5 or 13.6. I added to my original 16.3 position at retest and will trim this new position at 19.5 to give some cushion to my initialk position.
1 · Reply
ap20
ap20 Jun. 17 at 2:38 PM
$GLUE Stick with GLUE.
0 · Reply
wRsYUeX
wRsYUeX Jun. 11 at 1:35 AM
0 · Reply
DaSqueeza
DaSqueeza Jun. 8 at 2:21 PM
$GLUE i was in glue in september 25 ! it went from 5 to 9 and back to 6
1 · Reply
DaSqueeza
DaSqueeza Jun. 8 at 2:16 PM
$NRIX $GLUE was also sold of the first day. we have a lot of retail in this stock and high SI. it wil take some time till this climbs to a new high!
1 · Reply
LabPsycho
LabPsycho Jun. 8 at 2:12 PM
$NRIX IMO, not a good omen for the protein degrader and biotech sector in general when a whopping $700M upfront barely moves the needle and market cap of a stock. Several weeks ago $CCCC got $20M from Roche and closed down on the news. $GLUE about 9 months ago got $120M from Novartis and it ran - that is how the times have changed. The adverse repercussions of the war are going into the exponential phase up and biotech is moving to the bottom of hedge investments.
1 · Reply
LabPsycho
LabPsycho Jun. 6 at 1:13 PM
$GLUE @oceanbleu A few months ago, I bracketed GLUE price for 2026 to range between $10 and $30 for the year. Could be a lot of selling after October where many can start to claim long term capital gains (about a year after the big rise up). I think 30 might be a tough goal now with what I expect to be a massive retrace for most biotechs (many up 200-1000% in a year) for the remainder of the year.
1 · Reply
oceanbleu
oceanbleu May. 27 at 2:40 PM
$GLUE The last long entry recommended on GLUE was 16.3$ and the target1 is 22.8$ above . Glue is a long term position, but I will still be taking some profits at 22.8. I expect 22.8/26.5 to be a hard area to bypass initially. Note there is good accumulation on daily and weekly below 19 level.
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 2:12 AM
$GLUE Share Price: $19.19 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $4.28 – $5.29 Target Zone: $7.09 – $8.67 Potential Upside: 56% ROI Time to Expiration: 142 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 1:36 PM
Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $HYPR - 898,720 $LYEL - 293,256 $MAZE - 1,388,583 $GLUE - 684,275 $OSCR - 481,988 Google's Q1 13F reveals a sharp focus: Cybersecurity Bedrock + AI Bio-Engineering! The stake in $HYPR is a massive signal—in a 2026 defined by AI deepfakes, Google is leaning on $HYPR's passwordless tech to fortify its Gemini ecosystem. Meanwhile, the heavy lifting in $MAZE and $GLUE proves Alphabet is no longer just indexing information, but indexing "cures" through AI-led protein modeling. With $OSCR hitting its profitability inflection point, do you think Google is just building an AI-health moat, or are we looking at the early days of its next multi-billion dollar "Other Bet" breakout? Let's discuss your top small-cap pick!
3 · Reply
LabPsycho
LabPsycho May. 7 at 4:49 PM
$GLUE Frankly, IMO, while the cash and some of their assets look good, I dont get why they are going after: hidradenitis suppurativa (arent there easy do it at home ways to address much of this?) and atherosclerosis - once you have mineral deposits no drug is going to reverse (thermodynamics) that unless you sonicate or go in with a potent calcium chelator, those nodules are likely sticking around. I like that they did the offering around $24. Nice cash pile. Good luck
2 · Reply
ap20
ap20 May. 6 at 4:43 PM
$GLUE nothing posted this month..so I’ll stick with: Stick With GLUE.
0 · Reply
The_Gambl3r
The_Gambl3r Apr. 29 at 7:40 PM
$GLUE 👀👀👀👀👀👀
0 · Reply
cheruskian
cheruskian Apr. 28 at 8:49 PM
$SPY PSA: cup and handle patterns forming on the daily/weekly chart of several US biotechs. Check your favorite tickers and shop around a bit. E.g. waiting for confirmation breakout here $GLUE
0 · Reply
focafoca99
focafoca99 Apr. 20 at 1:40 PM
$GLUE presented AACR preclinical data supporting its CCNE1-directed molecular glue degrader in CCNE1-amplified solid tumors.
0 · Reply